{"id":299508,"date":"2026-10-09T16:51:32","date_gmt":"2026-10-09T11:21:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=299508"},"modified":"2026-10-09T16:51:32","modified_gmt":"2026-10-09T11:21:32","slug":"aarti-drugs-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/","title":{"rendered":"Aarti Drugs Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Aarti Drugs share price Rs 412.40 (9 October 2026). Base target Rs 444, bull Rs 539, downside risk Rs 332. PE 19.82. 52W range Rs 318.95 to Rs 534.00.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Aarti Drugs share price target for 2027 is Rs 444, about 7.7% above the current price of Rs 412.40. The bull case is Rs 539, and the downside risk level, which is not a target, is Rs 332. The base case assumes earnings per share grow 7.0% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 19.82. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing an Aarti Drugs target price for 2027 should start with where the stock sits today. At Rs 412.40 on 9 October 2026, it is 22.8% below its 52-week high of Rs 534.00 and 29.3% above its 52-week low of Rs 318.95. That range spans 67% from low to high, so the entry point matters as much as the Aarti Drugs price forecast itself.<\/p>\n<p>This article builds the Aarti Drugs share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 444 base case and the Rs 539 bull case were reached, along with a downside risk level of Rs 332.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aarti-drugs-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Aarti_Drugs_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Aarti Drugs Stock Analysis: Company Overview and Key Stats\">Aarti Drugs Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Why_Is_Aarti_Drugs_Share_Price_Target_Set_at_Rs_444_for_2027\" title=\"Why Is Aarti Drugs Share Price Target Set at Rs 444 for 2027?\">Why Is Aarti Drugs Share Price Target Set at Rs 444 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Earnings_Growth_Behind_the_Aarti_Drugs_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Aarti Drugs Target Price: Five Years of Results\">Earnings Growth Behind the Aarti Drugs Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Valuation_Check_for_the_Aarti_Drugs_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Aarti Drugs Stock Target: PE, Price to Book and ROE\">Valuation Check for the Aarti Drugs Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Aarti_Drugs_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Aarti Drugs Share Price Targets for the Short Term and 12 Months\">Aarti Drugs Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Short_Term_Aarti_Drugs_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Aarti Drugs Stock Target Levels: Technical Setup\">Short Term Aarti Drugs Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#12_Month_Aarti_Drugs_Target_Price_for_2027\" title=\"12 Month Aarti Drugs Target Price for 2027\">12 Month Aarti Drugs Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Aarti_Drugs_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Aarti Drugs Target Price\">How EPS Growth and PE Multiple Change the Aarti Drugs Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Aarti_Drugs_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Aarti Drugs Stock Target in 2027\">Bull Case and Downside Risk for Aarti Drugs Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Bull_Case_Rs_539\" title=\"Bull Case Rs 539\">Bull Case Rs 539<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Downside_Risk_Level_Rs_332\" title=\"Downside Risk Level Rs 332\">Downside Risk Level Rs 332<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Key_Risks_to_the_Aarti_Drugs_Target_Price_for_2027\" title=\"Key Risks to the Aarti Drugs Target Price for 2027\">Key Risks to the Aarti Drugs Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Aarti_Drugs_Price_Target\" title=\"Growth Slowdown Risk for the Aarti Drugs Price Target\">Growth Slowdown Risk for the Aarti Drugs Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#How_to_Invest_in_Aarti_Drugs\" title=\"How to Invest in Aarti Drugs\">How to Invest in Aarti Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#FAQs_on_Aarti_Drugs_Share_Price_Target_2027\" title=\"FAQs on Aarti Drugs Share Price Target 2027\">FAQs on Aarti Drugs Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_is_the_Aarti_Drugs_share_price_target_for_2027\" title=\"What is the Aarti Drugs share price target for 2027?\">What is the Aarti Drugs share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_is_the_Aarti_Drugs_share_price_today\" title=\"What is the Aarti Drugs share price today?\">What is the Aarti Drugs share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Is_Aarti_Drugs_a_buy_or_sell_at_the_current_price\" title=\"Is Aarti Drugs a buy or sell at the current price?\">Is Aarti Drugs a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Aarti_Drugs_shares\" title=\"What are the bull case target and downside risk level for Aarti Drugs shares?\">What are the bull case target and downside risk level for Aarti Drugs shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_are_the_main_risks_to_the_Aarti_Drugs_price_target\" title=\"What are the main risks to the Aarti Drugs price target?\">What are the main risks to the Aarti Drugs price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_is_the_PE_ratio_of_Aarti_Drugs_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Aarti Drugs and how does it compare with the industry?\">What is the PE ratio of Aarti Drugs and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#Who_owns_Aarti_Drugs_and_what_is_the_promoter_holding\" title=\"Who owns Aarti Drugs, and what is the promoter holding?\">Who owns Aarti Drugs, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/aarti-drugs-share-price-target-2027\/#What_were_Aarti_Drugs_latest_quarterly_results\" title=\"What were Aarti Drugs&#8217; latest quarterly results?\">What were Aarti Drugs&#8217; latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Aarti Drugs Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aarti Drugs (NSE: AARTIDRUGS) has a market capitalisation of Rs 3,788 crore. In FY26 it reported revenue of Rs 2,568 crore and net profit of Rs 194.94 crore. The table collects the figures the Aarti Drugs share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/aartidrugs\/aarti-drugs-ltd-share-price-today\">Aarti Drugs<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>AARTIDRUGS<\/td>\n<\/tr>\n<tr>\n<td>CMP (9 October 2026)<\/td>\n<td>Rs 412.40<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 534.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 318.95<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 3,788 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>19.82<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>37.59<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>2.45<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.58%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.37<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 20.94<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.48%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 444<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 539<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 332<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Aarti_Drugs_Share_Price_Target_Set_at_Rs_444_for_2027\"><\/span><strong>Why Is Aarti Drugs Share Price Target Set at Rs 444 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The base-case Aarti Drugs stock target of Rs 444 applies a PE multiple of 19.82 to a forward EPS estimate of Rs 22.41. That EPS assumes 7.0% yearly growth, the pace from FY24 to FY26, and puts the target 7.7% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Aarti_Drugs_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Aarti Drugs Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarti Drugs grew revenue from Rs 2,500 crore in FY22 to Rs 2,568 crore in FY26, a compound annual growth rate of 0.7%. Net profit grew more slowly, from Rs 205 crore to Rs 194.94 crore (-1.3% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>2,499.96<\/td>\n<td>205.00<\/td>\n<td>22.12<\/td>\n<td>1.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>2,718.25<\/td>\n<td>166.36<\/td>\n<td>17.97<\/td>\n<td>1.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>2,532.61<\/td>\n<td>171.59<\/td>\n<td>18.65<\/td>\n<td>1.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>2,403.39<\/td>\n<td>168.10<\/td>\n<td>18.35<\/td>\n<td>1.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>2,567.70<\/td>\n<td>194.94<\/td>\n<td>21.36<\/td>\n<td>2.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 6.8%, faster than the four-year average of 0.7%, and net profit moved up 16.0%. EPS rose from Rs 18.65 in FY24 to Rs 21.36 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarti Drugs converted 7.6% of FY26 revenue into net profit, against 7.0% in FY25, within a five-year range of 6.1% to 8.2%. EBITDA margin was 12.1% in FY26 versus 12.6% in FY25.<\/p>\n<p>In the June 2026 quarter, revenue was Rs 703.59 crore, up 19.1% from the same quarter a year earlier, while net profit of Rs 50.13 crore was down 7.1%. EBITDA came in at Rs 99.01 crore, up 33.1% year on year. The next quarterly result is the first test of whether the earnings assumption holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.37, and shareholders&#8217; equity grew from Rs 1,036 crore in FY22 to Rs 1,549 crore in FY26. Operating cash flow in FY26 was Rs 253.54 crore against capital expenditure of Rs 173.32 crore, leaving free cash flow of Rs 80.22 crore, or 2.1% of the current market capitalisation. In FY25 free cash flow was Rs 67.42 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Aarti_Drugs_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Aarti Drugs Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 19.82 against an industry PE of 37.59, Aarti Drugs trades at a discount to its industry. Price to book is 2.45 on a book value of Rs 169.70 per share, and return on equity is 12.58%. A PE of 19.82 equals an earnings yield of 5.0%, and the FY26 dividend of Rs 2.00 per share gives a yield of 0.48%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 54.43% of Aarti Drugs in June 2026, and promoter holding fell from 55.22% in June 2025 to 54.43% in June 2026. Foreign institutional investors (FII) held 1.52% and domestic institutions (DII) held 10.29%, which puts total institutional holding at 11.81%. FII holding fell from 2.26% in June 2025 to 1.52% in June 2026. Public shareholders own the remaining 33.75%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarti_Drugs_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Aarti Drugs Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Aarti_Drugs_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Aarti Drugs Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 412.40 on 9 October 2026, Aarti Drugs trades below its 50-day simple moving average of Rs 422.28 and above its 200-day exponential moving average of Rs 407.89. The 14-day RSI reads 38.8, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 422.28 (50-day simple moving average) and the nearest support is Rs 407.89 (200-day exponential moving average). A sustained move above Rs 422.28 would improve the short-term setup, while a close below Rs 407.89 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Aarti_Drugs_Target_Price_for_2027\"><\/span><strong>12 Month Aarti Drugs Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target for Aarti Drugs is Rs 444: forward EPS of Rs 22.41 at a PE of 19.82. That is 7.7% above Rs 412.40. It would still leave the stock 16.9% below its 52-week high of Rs 534.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Aarti_Drugs_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Aarti Drugs Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 15.86<\/th>\n<th>PE 19.82<\/th>\n<th>PE 22.79<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 20.94)<\/td>\n<td>Rs 332<\/td>\n<td>Rs 415<\/td>\n<td>Rs 477<\/td>\n<\/tr>\n<tr>\n<td>7.0% (EPS Rs 22.41)<\/td>\n<td>Rs 355<\/td>\n<td>Rs 444<\/td>\n<td>Rs 511<\/td>\n<\/tr>\n<tr>\n<td>13.0% (EPS Rs 23.67)<\/td>\n<td>Rs 375<\/td>\n<td>Rs 469<\/td>\n<td>Rs 539<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Aarti Drugs price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Aarti_Drugs_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Aarti Drugs Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_539\"><\/span><strong>Bull Case Rs 539<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Aarti Drugs price target needs EPS growth of 13.0%, which lifts forward EPS to Rs 23.67, and a PE multiple that rises 15% to 22.79. That gives Rs 539, 30.7% above the current price and above the 52-week high of Rs 534.00, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_332\"><\/span><strong>Downside Risk Level Rs 332<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 20.94 and the PE falls 20% to 15.86. That gives Rs 332, 19.5% below the current price and above the 52-week low of Rs 318.95.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>13.0%<\/td>\n<td>22.79<\/td>\n<td>Rs 539<\/td>\n<td>+30.7%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>7.0%<\/td>\n<td>19.82<\/td>\n<td>Rs 444<\/td>\n<td>+7.7%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>15.86<\/td>\n<td>Rs 332<\/td>\n<td>-19.5%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Aarti_Drugs_Target_Price_for_2027\"><\/span><strong>Key Risks to the Aarti Drugs Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Aarti_Drugs_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Aarti Drugs Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the June 2026 quarter was up 19.1% year on year, and FY26 revenue growth was 6.8%. If growth slows from here, the EPS estimate behind the Aarti Drugs stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarti Drugs has a market capitalisation of Rs 3,788 crore. Institutional holding is 11.81%, and promoters hold 54.43%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 7.6% in FY26, so a small slip in costs moves profit noticeably. At a PE of 19.82 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 15.86 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades 22.8% below its 52-week high, with an RSI of 38.8 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Aarti_Drugs\"><\/span><strong>How to Invest in Aarti Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Aarti Drugs share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 412.40 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Aarti Drugs&#8217; PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Aarti Drugs fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Aarti Drugs target price scenarios with your own view. If you expect EPS growth below 7.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aarti Drugs live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aarti Drugs share price target for 2027 is Rs 444 in the base case, with Rs 539 as the bull case. The support for that view is arithmetic you can check: EPS grew 7.0% a year over FY24 to FY26, and the stock trades at a PE of 19.82. The risks are equally concrete, including a stock that sits 22.8% below its 52-week high and a downside scenario that cuts the price 19% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Aarti_Drugs_Share_Price_Target_2027\"><\/span><strong>FAQs on Aarti Drugs Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Aarti_Drugs_share_price_target_for_2027\"><\/span><strong>What is the Aarti Drugs share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Aarti Drugs share price target for 2027 is Rs 444, with Rs 539 as the bull case. The downside risk level, which is not a target, is Rs 332. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Aarti_Drugs_share_price_today\"><\/span><strong>What is the Aarti Drugs share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 9 October 2026, 12:52 PM IST, Aarti Drugs trades at Rs 412.40, down 0.39% on the day. The 52-week range is Rs 318.95 to Rs 534.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aarti_Drugs_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Aarti Drugs a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data is mixed rather than one-sided: EPS has grown 7.0% a year over FY24 to FY26, but the stock is 22.8% below its 52-week high. Whether Aarti Drugs fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Aarti_Drugs_shares\"><\/span><strong>What are the bull case target and downside risk level for Aarti Drugs shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case target is Rs 539, which assumes 13.0% EPS growth and a PE of 22.79. The downside risk level is Rs 332, which assumes flat EPS and a PE of 15.86. It marks a risk, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Aarti_Drugs_price_target\"><\/span><strong>What are the main risks to the Aarti Drugs price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are slower revenue growth, a small market capitalisation of Rs 3,788 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Aarti_Drugs_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Aarti Drugs and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Aarti Drugs is 19.82 against an industry PE of 37.59. Price to book is 2.45 and return on equity is 12.58%. The base case in the Aarti Drugs price target holds this PE constant.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Aarti_Drugs_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Aarti Drugs, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 54.43% of Aarti Drugs in June 2026. FII held 1.52%, DII held 10.29% and the public held 33.75%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Aarti_Drugs_latest_quarterly_results\"><\/span><strong>What were Aarti Drugs&#8217; latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the June 2026 quarter, Aarti Drugs reported revenue of Rs 703.59 crore (up 19.1% year on year) and net profit of Rs 50.13 crore (down 7.1%).<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Aarti Drugs share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Aarti Drugs share price target for 2027 is Rs 444, with Rs 539 as the bull case. The downside risk level, which is not a target, is Rs 332. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.\"}},{\"@type\":\"Question\",\"name\":\"What is the Aarti Drugs share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 9 October 2026, 12:52 PM IST, Aarti Drugs trades at Rs 412.40, down 0.39% on the day. The 52-week range is Rs 318.95 to Rs 534.00.\"}},{\"@type\":\"Question\",\"name\":\"Is Aarti Drugs a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data is mixed rather than one-sided: EPS has grown 7.0% a year over FY24 to FY26, but the stock is 22.8% below its 52-week high. Whether Aarti Drugs fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Aarti Drugs shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case target is Rs 539, which assumes 13.0% EPS growth and a PE of 22.79. The downside risk level is Rs 332, which assumes flat EPS and a PE of 15.86. It marks a risk, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Aarti Drugs price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are slower revenue growth, a small market capitalisation of Rs 3,788 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Aarti Drugs and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Aarti Drugs is 19.82 against an industry PE of 37.59. Price to book is 2.45 and return on equity is 12.58%. The base case in the Aarti Drugs price target holds this PE constant.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Aarti Drugs, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 54.43% of Aarti Drugs in June 2026. FII held 1.52%, DII held 10.29% and the public held 33.75%.\"}},{\"@type\":\"Question\",\"name\":\"What were Aarti Drugs' latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the June 2026 quarter, Aarti Drugs reported revenue of Rs 703.59 crore (up 19.1% year on year) and net profit of Rs 50.13 crore (down 7.1%).\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aarti Drugs share price target 2027: base Rs 444, bull Rs 539, downside risk level Rs 332, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":28,"featured_media":299507,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-299508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["299507"],"rank_math_title":["Aarti Drugs Share Price Target 2027: Base and Bull Case"],"rank_math_description":["The Aarti Drugs share price target for 2027 is Rs 444 versus Rs 412.40 today. Bull case, downside risk, earnings trend and risks explained. October 2026."],"rank_math_focus_keyword":["Aarti Drugs share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/aarti-drugs-share-price-target-2027-base-and-bull-targets-built-on-fy26-earnings.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=299508"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299508\/revisions"}],"predecessor-version":[{"id":299509,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/299508\/revisions\/299509"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/299507"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=299508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=299508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=299508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}